Search PubMed⌕ Search

Biomedical subjects

N Goldblum

Publications and source records attributed to N Goldblum.

At least 37 records · Page 2Linked to original sources
PubMed1980

On the continuous culturing of B.95-8 cells in the presence of phosphonoacetic acid.

Lymphoblastoid B.95-8 cells were cultured for four months and three weeks in the presence of increasing concentrations (50--200 microgram/ml) of phosphonoacetic acid (PAA). Several weeks after removal of the PAA, the cultures, in parallel with untreated B.95-8 cells, were tested for the presence of: 1) Epstein-Barr virus (EBV) viral capsid antigen (VCA), and b) transformation of human cord blood lymphocytes. There was no difference in the percentage of cells exhibiting VCA in the B.95-8 PAA treated and untreated cells. However, transformation assays indicated 10 times less transforming virus in culture supernatant harvested from B.95-8 cultures treated with PAA, as compared with the control cultures. Electron microscopic studies indicated the presence of virus particles in B.95-8 control cells and their almost complete absence in the PAA-treated cells.

Antigens, Viral↗
PubMed1980

Clustering of Hodgkin's disease in Israel: a case-control study.

The geographical distribution of Jewish patients in Israel with HD diagnosed between 1960 and 1972 differed significantly from that of individually-matched population controls. Significant clustering occurred in 3 regions of the country. The odds ratio expressing the greater tendency of patients to have lived in one of these regions 5-9 years before the diagnosis, as compared with that of their paired controls, was 2.4. The association with residence in a higher-risk region was not significantly modified by sex, age, period of immigration, region of birth, father's region of birth, or date of diagnosis. The association was weaker for cases with nodular sclerosis than for those with other subtypes of HD. The clustering could not be explained by available data on the characteristics and prior experience of the cases and controls. There was a significant correlation between the risk of HD in a region and the proportion of native Israelis in its Jewish population, but there were no significant correlations with a variety of other demographic, natural and socioeconomic features of the regions. There was no significant time-space interaction. The findings suggest that susceptible people living in certain parts of the country during the 1950's and 1960's had a somewhat enhanced risk of HD because of exposure to unidentified environmental factors active in those regions at that time.

Adolescent↗
PubMed1980

Esters of phosphonopropionic and phosphonoacetic acids: effect on synthesis of Epstein-Barr virus (EBV) antigens and on transformation of cord blood lymphocytes by EBV.

Cell cytotoxicity, inhibition of synthesis of Epstein-Barr virus (EBV) viral capsid antigen (VCA), nuclear antigen (EBNA) and transformation of human cord blood lymphocytes (CBL) by EBV, were studied using the disodium salt of phosphonoacetic acid (PAA), ethyl diethyl-phosphonoacetate (Et-PAA) and two derivatives of phosphonopropionic acid: ethyl diethyl-2-phosphonopropionate (Et-2-PPA) and ethyl diethyl-3-phosphonopropionate (Et-3-PPA). These substances were tested on EBV producing cell lines, B.95-8 and P3HR1. VCA and EBNA synthesis were determined by immunofluorescence and transformation of CBL by 3H-thymidine uptake. Up to 100 micrograms/ml of PAA were not toxic to 2.10(5) cells. Et-PAA, Et-2-PPA and Et-3-PPA were nontoxic at concentrations up to 2000 micrograms/ml. PAA inhibited 82.05% of EBV VCA synthesis at a concentration of 50 micrograms/ml. Et-PAA inhibited 47.01% of VCA at a concentration of 100 micrograms/ml and 78.09% at a concentration of 2000 micrograms/ml. Et-2-PPA inhibited 41.04% of VCA at 100 micrograms/ml and 80.87% when used at 2000 micrograms/ml. Et-3-PPA inhibited 35.06% of VCA at 100 micrograms/ml and 69.92% at 2000 micrograms/ml. Removal of the substances restored VCA synthesis. EBNA synthesis was not affected by these substances. PAA completely inhibited the transformation of human CBL by EBV at a concentration of 100 micrograms/ml. Et-PAA at a concentration of 2000 micrograms/ml completely inhibited 3H-thymidine uptake. ET-2-PPA was less effective whereas Et-3-PPA had almost no effects at the same concentration.

Animals↗
PubMed1980

Sequential expression of fucosyltransferase and N-acetylneuraminyltransferase activities in human leukemic cells arrested at different stages of maturation.

Fucosyl transferase (Fuc-T) and N-acetylneuraminyl-transferase (NeuAc-T) activities were determined in lysates of human neoplastic hematopoietic cells arrested at different stages of maturation. Leukemic non-T/non-B lymphoblasts and myeloblasts arrested at a very early stage of maturation displayed high Fuc-T and low NeuAc-T activities. T-lymphoblasts, further developed along the T-lymphocyte lineage, showed increased NeuAc-T activity. In contrast, lymphoid cells further developed along the B-lymphocyte lineage revealed low Fuc-T, and either low or high levels of NeuAc-T activity. These results suggest that during the process of cell maturation the expression of Fuc-T precedes that of NeuAc-T, and that in T-lymphocytes the expression of NeuAc-T is concomitant with the emergence of the T-cell receptor for sheep erythrocytes.

Fucosyltransferases↗
PubMed1979

Antibody to poliovirus in older children and young adults in Israel and the use of poliovaccines for the immunization of the seronegatives.

This report represents preliminary results of a more extensive study which is presently being carried out in Israel. The main aims of this study were twofold: (1) to carry out a survey of the state of immunity of children of various ages and of teenagers to the three poliovirus types and (2) to compare the antibody response of the seronegatives to the two kinds of presently available poliovaccines, the oral poliovaccine (O. P. V., Savin Vaccine) and the inactivated poliovaccine (I. P. V., Salk Vaccine).

Adolescent↗
PubMed1978

Concanavalin A receptors on the surface membrane of lymphocytes from patients with Burkitt's lymphoma, other malignant lymphomas, leukaemia and lymphoma cell lines.

Lymphocytes isolated from the peripheral blood and tumour tissues of patients with African Burkitt's lymphoma (BL) showed a reduced cap-forming ability and increased agglutinability by concanavalin A (con A) compared to normal lymphocytes. Lymphocytes from the blood of patients with chronic lymphocytic leukaemia, Hodgkin's disease and other malignant lymphomas showed a similar reduction in cap formation and increase in agglutination compared to normal lymphocytes, lymphocytes from patients with carcinoma, and lymphocytes from patients with non-malignant disorders. The cap formation of lymphocytes from a healthy donor or a lymphoma patient was independent of the source from which the cells were isolated, e.g., lymph-node, spleen or blood. Lymphoma cell lines established from tumours of BL patients and lymphoblastoid cell lines originating from other sources also exhibited an increased agglutination and reduced cap formation with con A. Further studies indicated that EBV-carrying human lymphoid lines had a reduced cap-forming ability compared to EBV-negative lines.

Burkitt Lymphoma↗
PubMed1977

Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75).

The isolation and establishment in vitro of a hitherto undescribed type of lymphocyte designated D.G.-75 is reported. The original inoculum was derived from the pleural effusion of a child with a primary abdominal lymphoma, which clinically and histologically resembled Burkitt's lymphoma. In addition to the absence of the EBV genome and EBV receptors, this line possesses a number of other properties which distinguish it from previously described lymphoblastoid cell lines. It has different growth characteristics and morphology; does not form EAC or E rosettes (representative of B and T) cell surface markers, respectively); possesses IgM-kappa immunoglobulins on the cell surface (B lymphocyte), has an unusually high cap-forming ability and low agglutinability with fluorescent concanavalin A. One homologue of the No.14 chromosome pair possesses extra chromatin material as revealed on chromosome banding. This abnormal chromosome marker is similar to that described in biopsies and cultured tumor cells from patients with African Burkitt's lymphoma.

Agglutination Tests↗
PubMed1976

Concanavalin A receptors on the surface membrane of lymphocytes from patients with African Burkitt's lymphoma and lymphoma cell lines.

Lymphocytes isolated from the peripheral blood and from tumor tissues of patients with African Burkitt's lymphoma have been studied for cap formation and agglutinability by Concanavalin A (Con A). Peripheral blood from healthy adult persons served as a normal control and blood from patients with carcinoma served as a non-lymphoma control. These studies included 29 patients with Burkitt's lymphoma, 93 with carcinoma, and 105 healthy adult persons, as well as tumor tissues from 13 patients with Burkitt's lymphoma. The great majority of the carcinomas were from the face and neck regions. Lymphocytes from the blood of the majority of patients with Burkitt's lymphoma, as well as those from tumor tissues, exhibited a reduced cap-forming ability (2-6%) and increased Con-A-induced agglutinability compared to lymphocytes from healthy normal donors and from patients with carcinoma, although some of the lymphocytes from patients with carcinoma had a somewhat lower range of cap formation than the lymphocytes from healthy donors. No difference was observed in the interaction with Con A of lymphocytes from the different types of carcinoma studied. Eight lymphoid cell lines were established in our laboratory from the tumor tissues of patients with Burkitt's lymphoma. The cap-forming ability and agglutinability by Con A of these lines was examined and compared to those of the "classical" lymphoma lines: Raji, Daudi and P3HR1. All cell lines exhibited an increased Con-A-induced agglutinability and a reduced cap-forming ability compared to normal lymphocytes, except for P3HR1 cells which exhibited a cap-forming ability of 15-20%. These findings are discussed in relation to the association of the lymphocytes with malignancy and as a possible aid in the differential diagnosis between malignant lymphomas and other diseases.

Agglutination↗
PubMed1975

Concanavalin A receptors on the surface membrane of lymphocytes from patient's with Hodgkin's disease and other malignant lymphomas.

Concanavalin A (Con A) induces movement of its receptors on the cell surface membrane. This induction results in a concentration of Con A site complexes on one pole of the cell to form a cap. A marked difference was found in the mobility of Con A receptor between lymphocytes from normal persons and lymphocytes from patients with Hodgkin's disease and other malignant lymphomas. Lymphocytes isolated from tonsils of patients undergoing tonsillectomy and from axillary lymph nodes of breast cancer patients exhibited approximately 30% of cells with caps, which is identical with the cap formation ability of normal lymphocytes. In biopsy material from patients with Hodgkin's disease and other malignant lymphomas, a significant decrease in the ability of the lymphocytes to form caps was observed. This difference in the mobility of Con A sites was even more pronounced in lymphocytes isolated from the peripheral blood. In 123 patients with Hodgkin's disease and other malignant lymphomas, cap formation ranged between 3 and 12%. The ability of cells, from a normal donor or a lymphoma patient, to form caps was independent of the source from which the lymphocytes were isolated, e.g., lymph node, spleen, or blood. Lymphocytes from patients with lymphoma were also agglutinated by Con A to a higher degree than normal lymphocytes. These findings are discussed in relation to the association of the lymphocytes with these malignancies and as a possible aid in their differential diagnosis.

Agglutination↗